Pharmacogenetics and pharmacogenomics of sexual dysfunction: Current status, gaps and potential applications

Pharmacogenomics

Volumn 10, Issue 10, 2009, Pages 1625-1644

  Abdel Hamid, Ibrahim A ^a   Andersson, Karl Erik ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Androgens; PDE5 inhibitors; Pharmacogenetics; Pharmacogenomics; Phosphodiesterase 5 inhibitors; Serotonin reuptake inhibitors; Sexual dysfunction; SSRIs

Indexed keywords

ANDROGEN RECEPTOR; CITALOPRAM; CYCLIC GMP; CYTOCHROME P450; DAPOXETINE; DIPEPTIDYL CARBOXYPEPTIDASE; DRUG METABOLIZING ENZYME; GLUTAMATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE SYNTHASE; NORETHISTERONE ENANTATE; PAROXETINE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; TRAMADOL; UDENAFIL; VARDENAFIL;

ANOREXIA; ANORGASMIA; APPETITE; CHOLESTATIC HEPATITIS; CLUSTER HEADACHE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GYNECOMASTIA; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGONADISM; INFECTION; INFERTILITY; INJECTION SITE REACTION; INSOMNIA; LIBIDO; LIVER TUMOR; LOCAL SKIN REACTION; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MICROPENIS; MIGRAINE; NAUSEA; NONHUMAN; NOSE CONGESTION; ORGASM DISORDER; PHARMACOGENETICS; PHARMACOGENOMICS; PREMATURE EJACULATION; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SWEATING; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FEMALE; GENETIC VARIATION; GENOMICS; GENOTYPE; GUIDELINES AS TOPIC; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TERMINOLOGY AS TOPIC;

EID: 70649092307     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.104     Document Type: Review

References (178)

1. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States. JAMA 281, 537-544 (1999).
2. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ: Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch. Intern. Med. 166, 207-212 (2006). (Pubitemid 43144945)
3. Fischer ME, Vitek ME, Hedeker D, Henderson WG, Jacobsen SJ, Goldberg J: A twin study of erectile dysfunction. Arch. Intern. Med. 164, 165-168 (2004).
4. Richardson D, Goldmeier D: Premature ejaculation - does country of origin tell us anything about etiology. J. Sex. Med. 2, 508-512 (2005). (Pubitemid 40975835)
5. Jern P, Santtila P, Witting K et al.: Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J. Sex. Med. 4, 1739-1749 (2007). (Pubitemid 47616867)
6. Shaw K, Puri K, Ruiz-Deya G, Hellstrom WJG: Racial considerations in the evaluation of Peyronie's disease. J. Urol. 165(Suppl.), 170 (2001).
7. Weayherall MW, Higgs DR, Weiss, H, Weatherall DJ, Serjeant GR: Phenotype/genotype relationships in sickle cell disease: a pilot twin study. Clin. Lab. Haematol. 27, 384-390 (2005). (Pubitemid 41784348)
8. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang J-H: Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the Male Attitudes Regarding Sexual Health Survey. J. Sex. Med. 4, 57-65 (2007). (Pubitemid 46002367)
9. Park JK, Kim W, Kim SW, Koh GY, Park SK: Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with erectile dysfunction. Int. J. Impot. Res. 11, 273-276 (1999). • Documents the association between angiotensin converting enzyme genetic polymorphisms and erectile dysfunction. (Pubitemid 29505067)
10. Mazo EB, Gamidov SI, Mamedov MN, Iremashvili VV: Association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and erectile dysfunction in patients with metabolic syndrome. Int. J. Impot. Res. 20, 68-72 (2008).
11. Rosas-Vargas H, Coral-Vazquez RM, Tapia R, Borja JL, Salas RA, Salamanca F: Glu298Asp endothelial nitric oxide synthase polymorphism is a risk factor for erectile dysfunction in the Mexican-Mestizo population. J. Androl. 25, 728-732 (2004). (Pubitemid 39096306)
12. Erkan E, Muslumanoglu AY, Oktar T, Sanli O, Ozbek U, Kadioglu A: Polymorphism of endothelial nitric oxide synthase gene in patients with erectile dysfunction. J. Sex. Med. 3, 69-75 (2006).
13. Lee YC, Huang CH, Wang CJ et al.: The associations among eNOS G894T gene polymorphism, erectile dysfunction and related risk factors. BJU Int. 100, 1116-1120 (2007).
14. Elliott L, Ashley-Koch AE, De Castro L et al.: Genetic polymorphisms associated with priapism in sickle cell disease. Br. J. Haematol. 137, 262-267 (2007). • First report on association between nitric oxide synthase genetic polymorphism and priapism. (Pubitemid 46537636)
15. Pirmohamed M: Pharmacogenetics and pharmacogenomics. J. Clin. Pharmacol. 52, 345-357 (2001).
16. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
17. Tsai YJ, Hoyme HE: Pharmacogenomics: the future of drug therapy. Clin. Genet. 62, 257-264 (2002).
18. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. 5, 645-656 (2004).
19. Lander ES, Linton LM, Birren B et al.: Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001). (Pubitemid 32165345)
20. Venter JC, Adams MD, Myers EW et al.: The sequence of the human genome. Science 291, 1304-1351 (2001).
21. Ellegren H: Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet. 5, 435-445 (2004).
22. Feuk L, Carson AR, Scherer SW: Structural variation in the human genome. Nat. Rev. Genet. 7, 85-97 (2006).
23. Wiwanitkit V: Correlation between angiotensin converting enzyme I/D polymorphism and erectile dysfunction: an appraisal. Sex. Disabil. 23, 109-113 (2005). •• First meta-analysis study to document the association between angiotensin converting enzyme genetic polymorphism and erectile dysfunction.
24. Janssen PK, Bakker SC, Réthelyi J et al.: Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J. Sex. Med. 6, 276-284 (2009). •• Seminal paper that was the first to report on the data that primary lifelong premature ejaculation may be associated with serotonin transporter polymorphisms.
25. Ozbek E, Tasci AI, Tugcu V et al.: Possible association of the 5-HTTLPR serotonin transporter promoter gene polymorphism with PE in a Turkish population. Asian J. Androl. 11, 351-355 (2009).
26. Waldinger MD, Janssen PK, Schweitzer DH: Hardy Weinberg equilibrium in genetic PE research remains critical to avoid misinterpretation. Asian J. Androl. 11, 524 (2009).
27. Taher A, Stief C, Raida M, Jonas U, Forssmann WG: Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int. J. Impot. Res. 4(Suppl. 2), 11 (1992) (Abstract).
28. Francis SH, Turko IV, Corbin JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1-52 (2001).
29. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA: Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93, 280-291 (2003). (Pubitemid 37048240)
30. Loughney K, Hill TR, Florio VA et al.: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3050-cyclic nucleotide phosphodiesterase. Gene 216, 139-147 (1998). (Pubitemid 28389111)
31. Yanaka N, Kotera J, Ohtsuka A et al.: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur. J. Biochem. 255, 391-399 (1998). (Pubitemid 28340247)
32. Lin C-S: Tissue expression, distribution, and regulation of PDE5. Int. J. Impot. Res. 16, S8-S10 (2004).
33. Lin CS, Xin ZC, Lin G, Lue TF: Phosphodiesterases as therapeutic targets. Urology 61, 685-691 (2003).
34. Bender AT, Beavo JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520 (2006).
35. Salvi F, Sarzani R, Giorgi R et al.: Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). Int. J. Impot. Res. 16, 412-417 (2004).
36. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC: ACE polymorphisms. Circ. Res. 98, 1123-1133 (2006).
37. Becker AJ, Uckert S, Stief CG et al.: Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 57, 193-198 (2001). (Pubitemid 32065855)
38. Kim SZ, Kim SH, Park YK, Cho KW: Renin angiotensin system in rabbit corpus cavernosum: functional characterization of angiotensin II receptors. J. Urol. 158, 653-658 (1997).
39. Iwamoto Y, Song K, Takai S et al.: Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum. J. Pharmacol. Exp. Ther. 298, 43-48 (2001). (Pubitemid 32574508)
40. Eisenhardt A, Sperling H, Hauck E et al.: ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction. Urology 62, 152-157 (2003). •• First paper, to our knowledge, demonstrating that response to sildenafil in men with erectile dysfunction may be associated with ACE I/D polymorphism. (Pubitemid 36802105)
41. Becker AJ, Uckert S, Stief CG et al.: Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 57, 193-198 (2001). (Pubitemid 32065855)
42. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346 (1990). (Pubitemid 20370444)
43. Sperling H, Eisenhardt A, Virchow S et al.: Sildenafil response is influenced by the G protein β3 subunit GNB3 C825T polymorphism: a pilot study. J. Urol. 169, 1048-1051 (2003). •• First paper, to our knowledge, demonstrating that response to sildenafil in men with erectile dysfunction may be associated with the GNB3 C825T polymorphism. (Pubitemid 36188156)
44. Baumgart D, Naber C, Haude, M et al.: G protein β3 subunit 825T allele and enhanced coronary vasoconstriction on α(2)-adrenoceptor activation. Circ. Res. 85, 965-969 (1999). (Pubitemid 29534172)
45. Lindemann M, Virchow S, Ramann F et al.: The G protein β3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Lett. 495, 82-86 (2001). (Pubitemid 32367978)
46. Siffert W: Cardiovascular pharmacogenetics: on the way toward individually tailored drug therapy. Kidney Int. 63, S168-S171 (2003).
47. Torfgard K, Ahlner J, Axelsson KL: Relaxation of bovine mesenteric arteries by glyceryl trinitrate and other nitrocompounds: evidence for partly different mechanisms of action. Pharmacol. Toxicol. 67, 216-221 (1990). (Pubitemid 20352103)
48. Siffert W, Forster P, Jockel KH et al.: Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J. Am. Soc. Nephrol. 10, 1921-1930 (1999).
49. Gupta S, Moreland RB, Daley JT, Yang S, Goldstein I, Traish AM: Corpus cavernosum smooth muscle expresses functional post-synaptic α-2-adrenergic receptors. Br. J. Pharmacol. 123, 1237-1245 (1998). (Pubitemid 28120524)
50. Traish AM, Moreland RB, Huang Y-H, Goldstein I: Expression of functional α-2-adrenergic receptor subtypes in human corpus cavernosum and in human corpus cavernosum smooth muscle cells. Recept. Signal Transduct. 7, 55-67 (1997).
51. Wenzel RR, Siffert W, Bruck H, Philipp T, Schafers RF: Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics 12, 489-495 (2002). (Pubitemid 34913532)
52. Miyamoto Y, Saito Y, Kajiyama N et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32, 3-8 (1998). (Pubitemid 28324117)
53. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J: Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett. 471, 45-50 (2000). (Pubitemid 30173290)
54. Peskircioglu L, Atac FB, Erdem SR, Deveci S, Verdi H, Ozkardes H: The association between intron 4 VNTR, E298A and IVF 23 10 G/T polymorphisms of ecNOS gene and sildenafil responsiveness in patients with erectile dysfunction. Int. J. Impot. Res. 19, 149-153 (2007). (Pubitemid 46340833)
55. Seftel AD: Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin. Cardiol. 27(Suppl. 1), I14-I19 (2004).
56. Bischoff E: Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int. J. Impot. Res. 16(Suppl. 1), S34-S37 (2004).
57. Shim HJ, Kim YC, Park KJ et al.: Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J. Pharm. Sci. 92, 2185-2195 (2003).
58. Oh EY, Bae SK, Kwon JW, You M, Lee DC, Lee MG: Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. Brit. J. Pharmacol. 151, 24-34 (2007). (Pubitemid 46676001)
59. Lee HS, Park EJ, Ji HY et al.: Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica 38, 21-33 (2008).
60. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Ann. Rev. Med. 57, 119-137 (2006).
61. Ingelman-Sundberg M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. 369, 89-104 (2004).
62. Omari AA, Murry DJ: Pharmacogenetics of the cytochrome P450 enzyme system: review of current knowledge and clinical significance. J. Pharm. Pract. 20(3), 206-218 (2007).
63. Flores-Murrieta FJ, Castaneda-Hernandez G, Granados-Soto V, Herrera JE: Increased bioavailability of sildenafil in Mexican men. JAMA 283, 1825-1826 (2000).
64. Jetter A, Lazar A, Schömig E, Fuhr U, Kinzig-chippers M, Sörgel F: The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 78, 441-443 (2005). (Pubitemid 41393681)
65. Ku HY, Ahn HJ, Seo KA et al.: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab. Dispos. 36, 986-990 (2008).
66. Lindquist M: The need for definitions in pharmacovigilance. Drug Safety 30, 825-830 (2007).
67. Souverein PC, Egberts AC, Meuleman EJ, Urquhart J, Leufkens HG: Incidence and determinants of sildenafil (dis) continuation: the Dutch cohort of sildenafil users. Int. J. Impot. Res. 14, 259-265 (2002). (Pubitemid 34947730)
68. Bella AJ, Brant WO, Lue TF, Brock GB: Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can. J. Urol. 13, 3233-3238 (2006).
69. Sato Y, Tanda H, Kato S, Onishi S, Nitta T, Koroku M: How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int. J. Urol. 14, 339-342 (2007). (Pubitemid 46669041)
70. Moreira SG Jr, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED: Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 56, 474-476 (2007).
71. Gudziol V, Mück-Weymann M, Seizinger O, Rauh R, Siffert W, Hummel T: Sildenafil affects olfactory function. J. Urol. 177, 258-261(2007).
72. Carson CC 3rd: Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol. Clin. North Am. 34, 507-515 (2007).
73. Goldstein I, Lue TF, Padma Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 14, 1397-1404 (1998).
74. Keating GM, Scott LJ: Vardenafil: a review of its use in erectile dysfunction. Drugs 63, 2673-2703 (2003).
75. Curran M, Keating G: Tadalafil. Drugs 63, 2203-2212 (2003).
76. Evans RW, Kruuse C: Phosphodiesterase-5 inhibitors and migraine. Headache 44, 925-926 (2004).
77. de L Figuerola M, Bruera O, Lestón J, Ferreiro J: Cluster headache attack due to sildenafil intake. Cephalalgia 26, 617-619 (2006).
78. Kruuse C, Thomsen LL, Birk S, Olesen J: Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126, 241-247(2003). (Pubitemid 36068573)
79. Rainero I, Rubino E, Valfrè W et al.: Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. J. Headache Pain 8, 152-156 (2007). (Pubitemid 47062586)
80. Bhasin S, Cunningham GR, Hayes FJ et al.: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 91, 1995-2010 (2006).
81. Seftel A: Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int. J. Impot. Res. 19, 2-24 (2007).
82. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. 172, 658-663 (2004). (Pubitemid 38900229)
83. Mulhall JP, Valenzuela R, Aviv N, Parker M: Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 63, 348-353 (2004). (Pubitemid 38234433)
84. Bolour S, Braunstein G: Testosterone therapy in women: a review. Int. J. Impot. Res. 17, 399-408 (2005).
85. Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French FS: Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am. J. Hum. Genet. 44, 264-269 (1989).
86. Davison SL, Bell R: Androgen physiology. Semin. Reprod. Med. 24, 71-77 (2006).
87. Heinlein CA, Chang C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. 16, 2181-2187 (2002).
88. Traish AM, Goldstein I, Kim NN: Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur. Urol. 52, 54-70 (2007). (Pubitemid 46803026)
89. Lubahn DB, Brown TR, Simantal JA, Higgs HN, Migeon CJ, Wilson EM: Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc. Natl Acad. Sci. USA 86, 9534-9538 (1989).
90. Lubahn DB, Joseph DR, Sullivan P, Willard HF, French FS, Wilson EM: Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240, 327-330 (1988). (Pubitemid 18116696)
91. Marcelli M, Tilley WD, Wilson CM, Griffin JE, Wilson JD, McPhaul MJ: Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. Mol. Endocrinol. 4, 1105-1116 (1990). (Pubitemid 20352008)
92. Faber PW, Kuiper GG, van Rooij HC, van der Korput JA, Brinkmann AO, Trapman J: The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol. Cell. Endocrinol. 61, 257-262 (1989).
93. Rajender S, Rajani V, Gupta NJ, Chakravarty B, Singh L, Thangaraj K: No association of androgen receptor GGN repeat length polymorphism with infertility in Indian men. J. Androl. 27, 785-789 (2006). (Pubitemid 44846018)
94. Canale D, Caglieresi C, Moschini C et al.: Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin. Endocrinol. (Oxf.) 63, 356-361(2005). (Pubitemid 41233456)
95. Albertelli MA, Scheller A, Brogley M, Robins DM: Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol. Endocrinol. 20, 1248-1260 (2006). (Pubitemid 43801229)
96. Zitzmann M, Nieschlag E: Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J. Clin. Endocrinol. Metab. 92, 3844-3853 (2007). •• An outstanding paper that concluded that androgen receptor gene CAG repeat length may be associated with the response to testosterone undecanoate therapy in hypogonadal men. (Pubitemid 47607632)
97. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E: Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J. Clin. Endocrinol. Metab. 88, 2049-2054 (2003). (Pubitemid 36549876)
98. Ishii T, Sasaki G, Hasegawa T, Sato S, Matsuo N, Ogata T: Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis. J. Urol. 172, 319-324 (2004).
99. Zitzmann M: Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat. Clin. Pract. Urol. 4, 161-166 (2007).
100. Rolf C, Nieschlag E: Potential adverse effects of long-term testosterone therapy. Baillieres Clin. Endocrinol. Metab. 12, 521-534 (1998). (Pubitemid 29121665)
101. Calof OM, Singh AB, Lee ML et al.: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. 60, 1451-1457 (2005).
102. Basaria S, Dobs AS: Safety and adverse effects of androgens: how to counsel patients. Mayo Clin. Proc. 79(4 Suppl.), S25-S32 (2004). (Pubitemid 38401762)
103. Barqawi A, Crawford ED: Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int. J. Impot. Res. 18, 323-328 (2006).
104. Wang C, Cunningham G, Dobs A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 2085-2098 (2004). (Pubitemid 38619836)
105. Gaylis FD, Lin DW, Ignatoff JM, Amling C, Tutrone RF, Cosgrove DJ: Prostate cancer in men using testosterone supplementation. J. Urol. 174, 534-538 (2005). (Pubitemid 40981594)
106. Shabsigh R, Crawford ED, Nehra A, Slawin KM: Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int. J. Impot. Res. 21, 9-23 (2009).
107. Porkka KP, Visakorpi T: Molecular mechanisms of prostate cancer. Eur. Urol. 45, 683-691 (2004).
108. Waldinger MD, Zwinderman H, Schweitzer DH, Olivier B: Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int. J. Impot. Res. 16, 369-381 (2004).
109. Abdel-Hamid IA, Jannini EA, Andersson KE: Premature ejaculation: focus on therapeutic targets. Expert Opin. Ther. Targets 13, 175-193 (2009).
110. Waldinger MD: Premature ejaculation: state of the art. Urol. Clin. North Am. 34, 591-599 (2007).
111. Waldinger MD: Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment. World J. Urol. 23, 102-108 (2005).
112. Olivier B, Chan JS, Pattij T et al.: Psychopharmacology of male rat sexual behavior: modeling human sexual dysfunctions? Int. J. Impot. Res. 18(Suppl. 1), S14-S23 (2006). (Pubitemid 44330308)
113. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of antidepressant medication intolerance. Am. J. Psych. 160, 1830-1835 (2003).
114. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH: Serotonin 2A-1438 G/A and G-protein b3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 31, 2281-2288 (2006). (Pubitemid 44413208)
115. Bishop JR, Ellingrod VL, Akroush M, Moline J: The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum. Psychopharmacol. 24, 207-215 (2009).
116. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ: Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 34, 1819-1828 (2009). • First large-scale candidate gene-based study to report on association between 5-hydroxytryptamine receptor polymorphisms, glutamate receptor polymorphisms and citalopram sexual side effects.
117. Steimer W, Müller B, Leucht S, Kissling W: Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin. Chim. Acta 308, 33-41 (2001). (Pubitemid 32537608)
118. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB: Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int. J. Impot. Res. 18, 104-110 (2006). (Pubitemid 43050030)
119. Thuerauf N, Lunkenheimer J: The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur. Arch. Psychiatry Clin. Neurosci. 256, 287-293 (2006). (Pubitemid 44285052)
120. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A: The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51, 278-287 (1992).
121. Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF 3rd, Bies RR: Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br. J. Clin. Pharmacol. 61, 558-569 (2006).
122. Sawamura K, Suzuki Y, Someya T: Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur. J. Clin. Pharmacol. 60, 553-557 (2004). (Pubitemid 39517907)
123. Berney P: Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues Clin. Neurosci. 7, 249-262 (2005).
124. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther. Drug Monit. 222, 143-154 (2000).
125. Zourkova A, Hadasova E: Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J. Sex. Marital Ther. 28, 451-461 (2002).
126. Zourková A, Cesková E, Hadasová E, Ravcuková B: Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J. Sex. Marital Ther. 33, 343-355 (2007).
127. McGahuey CA, Gelenberg AJ, Laukes CA et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex. Marital Ther. 26, 25-40 (2000).
128. Sattler R, Rothstein JD: Regulation and dysregulation of glutamate transporters. Handb. Exp. Pharmacol. 175, 277-303 (2006).
129. Palmada M, Centelles JJ: Excitatory amino acid neurotransmission. Pathways for metabolism, storage and reuptake of glutamate in brain. Front Biosci. 3, D701-D718 (1998).
130. Lodge D: The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 56, 6-21 (2009).
131. Hull EM, Dominguez JM: Getting his act together: roles of glutamate, nitric oxide, and dopamine in the medial preoptic area. Brain Res. 1126, 66-75 (2006).
132. Waldinger MD, Hengeveld MW, Zwinderman AH: Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br. J. Urol. 79, 592-595 (1997).
133. McMahon CG, Touma K: Treatment of premature ejaculation with paroxetine hydrochloride. Int. J. Impot. Res. 11, 241-245 (1999).
134. Pryor JL, Althof SE, Steidle C et al.: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368(9539), 929-937 (2006). (Pubitemid 44331385)
135. Safarinejad MR: Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology 33, 1259-1265 (2008).
136. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T: The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 6, 351-356 (2006). (Pubitemid 44480155)
137. Tanaka M, Kobayashi D, Murakami Y et al.: Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int. J. Neuropsychopharmacol. 11, 261-267 (2008). (Pubitemid 351231828)
138. Wagner JA: Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48, 631-651 (2008).
139. Constable S, Johnson MR, Pirmohamed M: Pharmacogenetics in clinical practice: Considerations for testing. Expert Rev. Mol. Diagn. 6, 193-205 (2006). (Pubitemid 44167148)
140. Jung HG, Shin JH, Kim KW et al.: Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor. Life Sci. 80, 699-708(2007).
141. Andrade E, Andrade PM, Borra RC, Claro J, Srougi M: cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil. BJU Int. 101, 508-512 (2008). (Pubitemid 351160932)
142. Zhang XH, Morelli A, Luconi M et al.: Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur. Urol. 47, 409-416 (2005). (Pubitemid 40248872)
143. Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, Gonzalez-Cadavid N: Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J. Sex. Med. 3, 84-95 (2006).
144. Tong Y, Tar M, Davelman F, Christ G, Melman A, Davies KP: Variable coding sequence protein A1 as a marker for erectile dysfunction. BJU Int. 98, 396-401 (2006).
145. March R: Challenges and opportunities of pharmacogenetics in drug development. Pers. Med. 3, 195-206 (2006).
146. Vizirianakis IS: Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. Clin. Pharmacokinet. 46, 807-824 (2007).
147. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004). (Pubitemid 41103619)
148. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. 10, 135-151 (2006).
149. Grossman I: Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics 8, 1449-1459 (2007).
150. Kirchheiner J, Brosen K, Dahl ML et al.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 104, 173-192 (2001). (Pubitemid 32762271)
151. Safarinejad MR, Hosseini SY: Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J. Clin. Psychopharmacol. 26, 27-31 (2006).
152. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA: Tramadol HCL has promise in on-demand use to treat premature ejaculation. J. Sex. Med. 5, 188-193 (2008).
153. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH: The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 60, 636-644 (1996). (Pubitemid 27025910)
154. Ellenhorn MJ, Sternad FA: Problems of drug interactions. J. Am. Pharmacol. Assoc. NS6, 62-68 (1996).
155. Zhang H, Cui D, Wang B et al.: Pharmacokinetic drug interactions involving 17α-ethinylestradiol: a new look at an old drug. Clin. Pharmacokinet. 46, 133-157 (2007). (Pubitemid 46193058)
156. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG: Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 4, 354-358 (2004). (Pubitemid 39600050)
157. Zineh I, Pebanco GD, Aquilante CL et al.: Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann. Pharmacother. 40, 639-644 (2006).
158. Drewe J, Gutmann H, Fricker G, Török M, Beglinger C, Huwyler J: HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 57, 1147-1152 (1999). (Pubitemid 29171690)
159. Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307.
160. Ji HY, Shim HJ, Yoo M, Park ES, Lee HS: Transport of a new erectogenic udenafil in Caco-2 cells. Arch. Pharm. Res. 30, 1168-1173 (2007).
161. Grant SF, Hakonarson H: Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev. Mol. Diagn. 7, 371-393 (2007).
162. Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD: Genome-wide association studies: progress and potential for drug discovery and development. Nat. Rev. Drug Discov. 7, 221-230 (2008). (Pubitemid 351321233)
163. Hipp JD, Davies KP, Tar M et al.: Using gene chips to identify organ-specific, smooth muscle responses to experimental diabetes: potential applications to urological diseases. BJU Int. 99, 418-430 (2007). •• Highlights the importance of genome-wide association studies in sexual dysfunctions. (Pubitemid 46103128)
164. Erol B, Bozdogan G, Akduman B et al.: eNOS gene intron 4 VNTR and exon 7-G894T polymorphisms in Turkish men with erectile dysfunction: a case control study. J. Sex. Med. 6, 1423-1429 (2009).
165. Lee YC, Wu WJ, Liu CC et al.: The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J. Sex. Med. (2009) (Epub ahead of print).
166. Safarinejad MR: Polymorphisms of the serotonin transporter gene and their relation to premature ejaculation in individuals from Iran. J. Urol. 181, 2656-2661 (2009).
167. Nolan VG, Baldwin C, Ma Q et al. Association of single nucleotide polymorphisms in Klotho with priapism in sickle cell anaemia. Brit. J. Haematol. 128, 266-272 (2005).
168. Hauck EW, Hauptmann A, Schmelz HU, Bein G, Weidner W, Hackstein H: Prospective analysis of single nucleotide polymorphisms of the transforming growth factor β-1 gene in Peyronie's disease. J. Urol. 169, 369-372 (2003). (Pubitemid 35461648)
169. Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL: Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome. J. Clin. Endocrinol. Metab. 90, 5041-5046 (2005). (Pubitemid 41262252)
170. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E: X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J. Clin. Endocrinol. Metab. 89, 6208-6217 (2004). (Pubitemid 39628435)
171. Härkönen K, Huhtaniemi I, Mäkinen J et al.: The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. Int J. Androl. 26, 187-194 (2003). (Pubitemid 36718211)
172. Huhtaniemi IT, Pye SR, Limer KL et al.: Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J. Clin. Endocrinol. Metab. 941, 277-284 (2009).
173. Ishii T, Sato S, Kosaki K et al.: Micropenis and the AR gene: mutation and CAG repeat-length analysis. J. Clin. Endocrinol. Metab. 8611, 5372-5378 (2001). (Pubitemid 33070262)
174. Hare L, Bernard P, Sánchez FJ et al.: Androgen receptor repeat length polymorphism associated with male-to-female transsexualism. Biol. Psychiatry 65, 93-96 (2009).
175. Tong Y, Tar M, Monrose V, DiSanto M, Melman A, Davies KP: hSMR3A as a marker for patients with erectile dysfunction. J. Urol. 178, 338-343 (2007). (Pubitemid 46898456)
176. US FDA: E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories: guidance for industry. Fed. Regist. 73, 19074 (2008) www.fda.gov/RegulatoryInformation/ Guidances/ucm129286.htm (Accessed 25 September 2009)
177. Pfizer prescription products www.pfizer.com/products/rx/prescription.jsp (Accessed 25 September 2009)
178. Cialis: Prescribing information www.cialis.com/common-pages/prescribe-pt- info.jsp (Accessed 25 September 2008)